PLAB 1 (UKMLA AKT) cardiovascular questions

ST elevation in leads II, III and aVF with reciprocal ST depression in I and aVL indicates an inferior STEMI, which is most commonly caused by occlusion of the right coronary artery. The right coronary artery supplies the inferior wall of the left ventricle in most people, and reciprocal changes in the high lateral leads confirm the ECG findings are due to true infarction rather than another cause. Recognising reciprocal change helps differentiate STEMI from pericarditis, which does not produce reciprocal depression. Inferior STEMIs also carry a risk of right ventricular involvement and bradyarrhythmia due to AV nodal branch ischaemia.

• A. The LAD supplies the anterior and septal walls, producing ST elevation in V1-V4, not II, III and aVF.
• B. Left main stem occlusion typically causes widespread ST elevation or depression across multiple territories, not an isolated inferior pattern.
• C. The circumflex artery supplies the lateral wall, producing changes in I, aVL, V5-V6.
• E. A septal perforator occlusion would cause anteroseptal changes in V1-V2, not an inferior pattern.

Current guidance recommends primary percutaneous coronary intervention (PCI) as the treatment of choice for STEMI when it can be delivered within 120 minutes of the time when fibrinolysis could have been given. Since the catheterisation laboratory is only 30 minutes away, transfer for primary PCI is feasible well within this window and is superior to fibrinolysis in restoring coronary flow and reducing mortality. Fibrinolysis is reserved for situations where timely PCI access is not possible. Aspirin has already been given appropriately, and the next priority is definitive reperfusion.

• A. Fibrinolysis is not first-line here because primary PCI is achievable well within the 120-minute target.
• B. ACE inhibitors are part of secondary prevention after the acute event, not the immediate management of ongoing STEMI.
• D. Delaying reperfusion therapy for hours is inappropriate and increases the risk of complications and death.
• E. Admitting locally without reperfusion therapy delays definitive treatment and increases myocardial damage.

When primary PCI cannot be delivered within 120 minutes of the time fibrinolysis could be given, fibrinolytic therapy should be administered promptly to restore coronary perfusion in STEMI, provided there are no contraindications such as active bleeding or recent haemorrhagic stroke. Fibrinolysis works by activating plasminogen to dissolve the occlusive coronary thrombus. The patient should also receive dual antiplatelet therapy and be transferred for angiography once stabilised, ideally within 24 hours. Time to reperfusion is the key determinant of outcome in STEMI, so fibrinolysis should not be delayed when PCI access is prolonged.

• A. Delaying treatment increases myocardial necrosis and mortality; immediate reperfusion therapy is required.
• C. Heparin alone does not achieve reperfusion of an occluded coronary artery in STEMI.
• D. Clopidogrel is an adjunct antiplatelet agent, not a reperfusion therapy, and does not dissolve existing thrombus.
• E. Bypass grafting is not performed emergently for acute STEMI reperfusion and requires significant preparation time.

The GRACE (Global Registry of Acute Coronary Events) score is used in NSTEMI and unstable angina to estimate in-hospital and 6-month mortality risk, and this risk stratification guides the timing of coronary angiography. Patients classified as intermediate or high risk should undergo angiography within 72 hours, while those with ongoing ischaemia, haemodynamic instability or life-threatening arrhythmias need immediate angiography. The GRACE score incorporates variables such as age, heart rate, blood pressure, creatinine, Killip class, cardiac arrest at presentation, ST-segment deviation and troponin level. It is distinct from scores used for stroke risk, bleeding risk, or venous thromboembolism.

• A. The Wells score is used to estimate the pre-test probability of venous thromboembolism.
• B. QRISK3 estimates 10-year cardiovascular risk for primary prevention, not acute risk stratification in ACS.
• C. HAS-BLED estimates bleeding risk in patients on anticoagulation for atrial fibrillation.
• D. CHA2DS2-VASc estimates stroke risk in atrial fibrillation, not ACS risk stratification.

Following ACS treated with PCI, guidelines recommend dual antiplatelet therapy with aspirin plus a potent P2Y12 inhibitor such as ticagrelor for 12 months, after which aspirin monotherapy is usually continued long-term. Ticagrelor and prasugrel are preferred over clopidogrel in ACS because they provide more rapid and consistent platelet inhibition, improving outcomes, although clopidogrel is used when ticagrelor or prasugrel are contraindicated or not tolerated, such as in patients with a high bleeding risk. The 12-month duration balances the reduction in stent thrombosis and recurrent ischaemic events against the increased bleeding risk of prolonged dual therapy. Warfarin and dipyridamole are not standard components of post-ACS antiplatelet regimens.

• A. One month is too short; standard DAPT duration after ACS with stenting is 12 months.
• B. Dipyridamole is used in secondary stroke prevention, not as part of standard post-ACS dual antiplatelet therapy.
• D. Prasugrel is an acceptable alternative, but 3 months is too short; the standard duration is 12 months and prasugrel is typically reserved for patients proceeding to PCI without prior clopidogrel exposure.
• E. Warfarin is an anticoagulant used for conditions like atrial fibrillation or mechanical valves, not routine post-ACS antiplatelet therapy.

Following myocardial infarction, beta-blockers and ACE inhibitors are recommended as standard secondary prevention because they reduce mortality and the risk of adverse cardiac remodelling. Beta-blockers reduce myocardial oxygen demand and the risk of arrhythmia, while ACE inhibitors reduce afterload and limit ventricular remodelling, particularly beneficial even in patients with only mildly reduced ejection fraction. Both are typically started once the patient is haemodynamically stable, with doses titrated upward as tolerated. This combination, alongside dual antiplatelet therapy and a high-intensity statin, forms the cornerstone of post-MI secondary prevention.

• A. Calcium channel blockers and loop diuretics are not first-line secondary prevention after MI and loop diuretics are reserved for fluid overload.
• B. Potassium-sparing diuretics and centrally acting antihypertensives are not standard post-MI secondary prevention agents.
• C. Thiazide diuretics and alpha-blockers are used for hypertension management, not as standard post-MI secondary prevention.
• D. Digoxin and nitrates do not reduce mortality post-MI and are not part of routine secondary prevention.

Dressler's syndrome is an autoimmune pericarditis that typically occurs 2-6 weeks after myocardial infarction, thought to result from an immune response to myocardial antigens exposed during infarction. It presents with pleuritic chest pain relieved by sitting forward, low-grade fever, pericardial friction rub, and raised inflammatory markers such as CRP and ESR, sometimes with a pericardial effusion on echocardiography. Treatment is typically with high-dose aspirin or NSAIDs, with colchicine as an adjunct for recurrent cases. It is distinguished from early post-MI pericarditis, which occurs within days rather than weeks.

• A. Recurrent MI would typically present with recurrence of typical ischaemic chest pain and ECG changes or troponin rise, not pleuritic pain relieved by sitting forward.
• C. Ventricular septal rupture occurs acutely in the days following MI and presents with acute heart failure and a new pansystolic murmur, not weeks later with pleuritic pain.
• D. Pulmonary embolism may cause pleuritic pain but would not typically cause a pericardial friction rub, and the clinical timing fits classic post-MI pericarditis better.
• E. Infective endocarditis would present with persistent fever, new murmur, and signs such as splinter haemorrhages, not a pattern typical of post-MI pericarditis.

Standard advice for GTN spray use is to stop the activity, sit down, and take one dose; if pain persists after five minutes, a second dose should be taken. If pain is still present five minutes after the second dose, an ambulance should be called, as this may indicate acute coronary syndrome rather than stable angina. This stepwise approach helps distinguish typical angina, which resolves with rest and GTN, from a potential myocardial infarction requiring emergency care. Patients should be counselled on this protocol at the time angina is first diagnosed.

• A. Lying flat and waiting is not appropriate; the stepwise GTN protocol with a clear escalation plan should be followed.
• B. Returning to activity before the pain has fully resolved and the protocol completed risks worsening ischaemia.
• C. A third dose should not be taken; after two doses with persistent pain, emergency help should be sought rather than further self-treatment.
• D. Continuing the triggering activity despite ongoing chest pain is unsafe advice regardless of aspirin use.

Verapamil, a non-dihydropyridine calcium channel blocker, has significant negative chronotropic and negative dromotropic effects on the atrioventricular node, similar to beta-blockers. Combining verapamil with a beta-blocker such as bisoprolol can cause severe bradycardia, atrioventricular block or asystole due to additive suppression of cardiac conduction. The BNF specifically advises against this combination. If a calcium channel blocker is needed alongside a beta-blocker, a dihydropyridine such as amlodipine, which lacks significant AV nodal effects, is preferred.

• A. Isosorbide mononitrate does not significantly affect AV nodal conduction and is commonly combined with beta-blockers.
• C. Amlodipine is a dihydropyridine calcium channel blocker with minimal AV nodal effect and can usually be combined safely with a beta-blocker.
• D. Ivabradine can cause bradycardia but does not carry the same risk of complete heart block as verapamil combined with a beta-blocker.
• E. Nicorandil does not cause clinically significant AV block when combined with beta-blockers.

Heart failure with reduced ejection fraction is defined by a left ventricular ejection fraction below 40%, reflecting impaired systolic function, which matches this patient's ejection fraction of 35% with global hypokinesia. Heart failure with preserved ejection fraction, by contrast, is defined by an ejection fraction of 50% or more with structural or functional abnormalities and symptoms of heart failure. The distinction is clinically important because evidence-based pharmacological therapies, such as ACE inhibitors, beta-blockers, mineralocorticoid receptor antagonists and SGLT2 inhibitors, have proven mortality benefit specifically in HFrEF. Echocardiographic measurement of ejection fraction is therefore central to guiding management.

• A. Preserved ejection fraction requires an ejection fraction of 50% or more, not 35%.
• B. This patient has systolic dysfunction, evidenced by a reduced ejection fraction and global hypokinesia, not isolated diastolic dysfunction.
• D. The echocardiogram describes left ventricular abnormalities, not isolated right heart failure.
• E. High-output heart failure occurs with a normal or increased ejection fraction due to excessive demand, not reduced systolic function.

Once an ACE inhibitor has been titrated to the maximum tolerated dose, NICE guidance recommends adding a beta-blocker licensed for heart failure, such as bisoprolol, carvedilol or nebivolol. Beta-blockers reduce mortality and hospitalisation in heart failure with reduced ejection fraction by blunting sympathetic overactivation. They should be started at a low dose and titrated slowly, with monitoring of heart rate and blood pressure. Amlodipine, digoxin, verapamil and doxazosin are not part of first-line disease-modifying therapy in this setting.

• A. Digoxin may help symptom control in later stages but is not the next first-line step after an ACE inhibitor.
• B. Doxazosin is an alpha-blocker with no established role in standard heart failure management.
• C. Verapamil is a negatively inotropic calcium channel blocker and is contraindicated in heart failure with reduced ejection fraction.
• E. Amlodipine is not part of standard first-line heart failure therapy and has no proven mortality benefit here.

Loop diuretics such as furosemide act on the thick ascending limb of the loop of Henle, producing potent diuresis that rapidly relieves congestive symptoms such as peripheral oedema and breathlessness. They are used for symptomatic relief in heart failure but do not form part of the mortality-reducing triad of ACE inhibitor, beta-blocker and mineralocorticoid receptor antagonist. Thiazide and thiazide-like diuretics are weaker and less effective for significant fluid overload. Dose should be titrated against clinical response, weight and renal function.

• A. Indapamide is a thiazide-like diuretic with insufficient potency for this degree of fluid overload.
• B. Spironolactone is added for prognostic benefit in persistent symptoms, not primarily for rapid symptomatic diuresis.
• C. Bendroflumethiazide is a thiazide diuretic with a weaker diuretic effect, unsuitable for significant fluid overload.
• D. Amiloride is a potassium-sparing diuretic with a mild effect, not appropriate for significant congestion.

Spironolactone is a mineralocorticoid receptor antagonist that blocks aldosterone-mediated sodium reabsorption and potassium excretion, predisposing to hyperkalaemia, particularly when combined with an ACE inhibitor. A potassium level of 6.1 mmol/L represents significant hyperkalaemia requiring discontinuation of the offending drug and further monitoring, even in the absence of ECG changes or symptoms. Continuing the drug risks worsening hyperkalaemia and life-threatening arrhythmia. Emergency treatments such as insulin-dextrose or calcium resonium are reserved for severe hyperkalaemia with ECG changes or very high potassium levels.

• A. Continuing spironolactone at this potassium level risks dangerous progression of hyperkalaemia.
• B. Increasing ramipril would further worsen hyperkalaemia, as ACE inhibitors also reduce potassium excretion.
• C. Insulin and dextrose are reserved for severe hyperkalaemia with ECG changes, not this stable, asymptomatic presentation.
• E. Calcium resonium is used for ongoing hyperkalaemia management, not as the immediate first step before stopping the causative drug.

Acute pulmonary oedema is a medical emergency managed by sitting the patient upright to reduce venous return and improve ventilation, giving high-flow oxygen to correct hypoxia, and administering intravenous furosemide to promote rapid diuresis and venodilation. Intravenous nitrates may be considered if blood pressure allows, to reduce preload further. Fluid boluses would worsen pulmonary congestion, and thiazide diuretics act too slowly for acute management. Beta-blockers are avoided acutely due to their negative inotropic effect in decompensated states.

• A. Non-invasive ventilation may be used as an adjunct in severe cases, but diuretic therapy and oxygen remain first-line initial measures.
• B. Oral thiazide diuretics have a slow onset of action, unsuitable for acute severe pulmonary oedema.
• D. Intravenous beta-blockers have a negative inotropic effect and can worsen acute decompensated heart failure.
• E. Intravenous fluids would worsen fluid overload and pulmonary congestion.

Classic chest radiograph findings in heart failure follow the 'ABCDE' mnemonic: Alveolar oedema (bat wing appearance), Kerley B lines (interstitial oedema), Cardiomegaly, upper lobe venous Diversion (due to redistribution of blood flow to upper lobes from increased pulmonary venous pressure), and pleural Effusions. Upper lobe venous diversion with bilateral pleural effusions reflects raised left atrial pressure causing pulmonary venous congestion, strongly supporting heart failure. The other findings are characteristic of malignancy, tuberculosis, pneumothorax, and aortic dissection respectively, not heart failure.

• A. Unilateral hilar lymphadenopathy suggests malignancy or sarcoidosis rather than heart failure.
• B. Pneumothorax with tracheal deviation indicates tension pneumothorax, an unrelated acute emergency.
• D. A widened mediastinum with a double aortic contour suggests aortic dissection, not heart failure.
• E. An apical cavitating lesion with consolidation is suggestive of tuberculosis, not heart failure.

Atrial fibrillation is characterised on ECG by an irregularly irregular rhythm, absence of distinct P waves due to chaotic atrial electrical activity, and narrow QRS complexes reflecting normal conduction through the His-Purkinje system. The absence of P waves distinguishes it from atrial flutter, which typically shows a sawtooth flutter wave pattern, and from multifocal atrial tachycardia, which shows at least three distinct P wave morphologies. Sinus arrhythmia produces a regularly irregular pattern linked to respiration, with normal P waves present.

• A. Ventricular ectopic beats would show broad, abnormal QRS complexes interspersed with normal sinus beats.
• C. Sinus arrhythmia is regularly irregular and associated with respiration, with normal P waves preserved.
• D. Multifocal atrial tachycardia shows at least three different P wave morphologies, not an absence of P waves.
• E. Atrial flutter typically shows a sawtooth pattern of flutter waves, which is absent here.

In all patients newly diagnosed with atrial fibrillation, stroke risk should be formally assessed using the CHA2DS2-VASc score before deciding on anticoagulation, as per NICE guidance. This patient has hypertension (1 point), diabetes (1 point), and age 65-74 or over 75 (1 or 2 points), giving a score that will warrant anticoagulation in most such cases, but the score must be calculated explicitly to guide the decision and select an appropriate agent. Aspirin is not recommended for stroke prevention in atrial fibrillation. Immediate cardioversion is not indicated in a stable patient without a clear onset within 48 hours, and anticoagulation decisions should not bypass formal risk stratification.

• A. Symptom status does not determine stroke risk; formal scoring is required regardless of symptoms.
• B. Immediate cardioversion is not indicated in a haemodynamically stable patient without confirmed onset within 48 hours and before anticoagulation status is addressed.
• C. Aspirin alone is not recommended for stroke prevention in atrial fibrillation according to current guidance.
• E. Anticoagulation decisions should always follow formal risk stratification using a validated score, not be started empirically.

NICE guidance recommends a direct oral anticoagulant, such as apixaban, rivaroxaban, dabigatran or edoxaban, as first-line therapy for stroke prevention in non-valvular atrial fibrillation, in preference to warfarin. DOACs have a more predictable pharmacokinetic profile, do not require routine coagulation monitoring, and have a lower risk of intracranial haemorrhage compared with warfarin. Warfarin remains first-line in specific situations such as significant renal impairment (creatinine clearance below 15 mL/min) or mechanical heart valves. Antiplatelet agents such as aspirin and clopidogrel are not effective for stroke prevention in atrial fibrillation.

• A. Low molecular weight heparin is not used for long-term stroke prevention in atrial fibrillation.
• B. Aspirin is not effective for stroke prevention in atrial fibrillation and is not recommended for this purpose.
• C. Clopidogrel, like other antiplatelet agents, is not effective for stroke prevention in atrial fibrillation.
• D. Warfarin is no longer first-line for non-valvular atrial fibrillation, being reserved for specific situations such as severe renal impairment or mechanical valves.

This patient has atrial fibrillation with adverse features (hypotension, confusion, signs of shock), meeting Resuscitation Council UK criteria for unstable tachycardia. The correct management is immediate synchronised DC cardioversion, with sedation or anaesthesia as the patient is conscious. Synchronisation ensures the shock is delivered on the R wave, avoiding the vulnerable period of the T wave which could precipitate ventricular fibrillation. Drug therapy is too slow and unreliable when a patient is haemodynamically unstable.

• B. Too slow in onset of action for acute unstable tachyarrhythmia.
• C. Too slow for an unstable patient with adverse features requiring immediate correction.
• D. Rate control alone does not address the haemodynamic instability requiring urgent rhythm correction.
• E. Unsynchronised shocks risk inducing ventricular fibrillation by discharging during the T wave; this is only used in pulseless arrest.

This is a stable regular narrow-complex tachycardia (most likely AV nodal re-entrant tachycardia) that has not responded to vagal manoeuvres. Per the Resuscitation Council UK tachycardia algorithm, the next step is intravenous adenosine, given as a rapid bolus followed by a saline flush, starting at 6 mg and increasing to 12 mg if needed. Adenosine transiently blocks conduction through the AV node, terminating re-entrant circuits that depend on it. It has a very short half-life (under 10 seconds), making its effects brief and generally well tolerated.

• B. Reserved as a second-line option if adenosine fails or is contraindicated.
• C. Not first-line for regular narrow-complex SVT unresponsive to vagal manoeuvres.
• D. Reserved for haemodynamically unstable tachycardia with adverse features, which this patient does not have.
• E. Not used acutely for terminating SVT in this setting; it is more relevant to chemical cardioversion of AF or long-term prophylaxis.

Adenosine can provoke severe bronchospasm and is relatively contraindicated in patients with asthma or significant reactive airway disease. In this situation, intravenous verapamil is the preferred alternative for terminating stable SVT, as it also slows conduction through the AV node without the bronchoconstrictive risk associated with adenosine. Verapamil should be avoided in patients with heart failure or those recently given beta-blockers due to the risk of severe hypotension or asystole.

• A. Too slow in onset to be useful for acute termination of SVT.
• B. Not first-line for simple re-entrant SVT; reserved for broad-complex or refractory arrhythmias.
• D. Used for rhythm control in AF or as a Pill-in-the-Pocket strategy, not for acute SVT termination.
• E. Beta-blockers are not the standard acute treatment for terminating SVT in this algorithm.

This patient is in cardiac arrest with pulseless ventricular tachycardia, a shockable rhythm. The priority is immediate defibrillation as part of the Resuscitation Council UK cardiac arrest algorithm, combined with high-quality chest compressions and ventilation. Amiodarone 300 mg is given after the third shock if the rhythm remains shockable, not as the initial step. Synchronisation is not used in cardiac arrest because the delay in finding an R wave would interrupt resuscitation.

• A. Synchronisation is unnecessary and potentially harmful in pulseless arrest, where immediate defibrillation is required.
• B. Given after the third defibrillation attempt in a shock-refractory shockable rhythm, not as the first action.
• C. Chest compressions alone are inadequate when a shockable rhythm is present; defibrillation must be delivered promptly.
• E. Not used in the management of cardiac arrest; relevant only to haemodynamically stable narrow-complex tachycardia.

This rhythm is pulseless electrical activity, a non-shockable rhythm despite showing organised electrical complexes, because there is no palpable cardiac output. Management follows the non-shockable arm of the Resuscitation Council UK algorithm: continue high-quality CPR, secure the airway, and give intravenous adrenaline 1 mg as soon as possible, repeated every 3–5 minutes, while identifying and treating reversible causes (the 4 Hs and 4 Ts). Defibrillation is not indicated because there is no chaotic or shockable electrical rhythm such as ventricular fibrillation or pulseless ventricular tachycardia.

• A. An organised rhythm without a pulse still represents cardiac arrest and requires continued resuscitation.
• B. Defibrillation is only indicated for shockable rhythms (VF or pulseless VT), not organised rhythms without a pulse.
• D. Synchronised cardioversion is used for unstable tachyarrhythmias in patients with a pulse, not in cardiac arrest.
• E. Adenosine has no role in cardiac arrest management.

This patient's cardiac arrest is due to severe hyperkalaemia (potassium 7.8 mmol/L), one of the 4 Hs (hyperkalaemia) in the reversible causes of cardiac arrest. Intravenous calcium gluconate stabilises the cardiac membrane by antagonising the effect of potassium on myocyte excitability and acts within minutes, making it the immediate priority during arrest. Insulin-dextrose and salbutamol shift potassium intracellularly but act more slowly and are adjuncts rather than the first-line emergency measure. Bicarbonate is reserved for severe acidosis or arrest due to tricyclic overdose, not as first-line hyperkalaemia treatment.

• A. Magnesium is used for torsades de pointes or refractory VF, not as the primary treatment for hyperkalaemia.
• C. Bicarbonate is not first-line for hyperkalaemic arrest; it is used mainly for severe acidosis or tricyclic antidepressant overdose.
• D. Insulin and dextrose shift potassium intracellularly but act too slowly to be the immediate priority in arrest.
• E. Salbutamol lowers potassium by intracellular shift but is an adjunct, not the immediate cardioprotective measure.

Aortic stenosis classically presents with an ejection systolic murmur radiating to the carotids, a slow-rising (anacrotic) pulse, and a soft or absent second heart sound due to reduced leaflet mobility. Exertional syncope occurs because the fixed stenotic valve prevents the cardiac output from rising to meet demand during exercise, causing a fall in cerebral perfusion. The combination of angina, syncope and breathlessness in aortic stenosis signals a poor prognosis and should prompt urgent echocardiography. Hypertrophic obstructive cardiomyopathy can mimic this but typically occurs in younger patients and the pulse is often jerky rather than slow-rising.

• A. Mitral regurgitation produces a pansystolic murmur radiating to the axilla, not an ejection systolic murmur radiating to the carotids.
• B. Atrial septal defect produces a fixed split second heart sound and a pulmonary flow murmur, not carotid radiation with a slow-rising pulse.
• D. Hypertrophic obstructive cardiomyopathy typically presents at a younger age with a jerky pulse, not a slow-rising pulse.
• E. Pulmonary stenosis produces an ejection systolic murmur loudest at the left upper sternal border, not radiating to the carotids.

Mitral regurgitation produces a pansystolic (holosystolic) murmur loudest at the apex that classically radiates to the axilla, with a soft first heart sound due to incomplete valve closure. Chronic mitral regurgitation leads to left atrial and ventricular volume overload, often causing atrial fibrillation (the irregular pulse here) and eventually pulmonary venous congestion with crackles. The murmur intensity does not correlate well with severity, and echocardiography is required to assess regurgitant volume and ventricular function. Tricuspid regurgitation produces a pansystolic murmur too, but it is loudest at the lower left sternal edge and radiates towards the sternum, not the axilla.

• A. A ventricular septal defect causes a harsh pansystolic murmur at the left lower sternal border, not radiating to the axilla.
• B. Tricuspid regurgitation causes a pansystolic murmur at the lower left sternal edge, not one radiating to the axilla.
• D. Aortic regurgitation causes an early diastolic murmur, not a pansystolic murmur.
• E. Aortic stenosis causes an ejection systolic murmur radiating to the carotids, not a pansystolic murmur radiating to the axilla.

Aortic regurgitation produces a wide pulse pressure (148/54 mmHg here) and a collapsing (water-hammer) pulse, due to a large stroke volume followed by rapid diastolic backflow into the left ventricle. The early diastolic murmur is best heard at the left sternal edge with the patient sitting forward in expiration, reflecting turbulent retrograde flow through the incompetent aortic valve during diastole. Causes include bicuspid aortic valve, rheumatic disease, infective endocarditis and aortic root dilatation (e.g. Marfan syndrome, aortitis). Echocardiography confirms the diagnosis and assesses left ventricular size and function, which guide timing of surgery.

• A. Tricuspid regurgitation causes a pansystolic murmur, not an early diastolic murmur.
• B. Pulmonary regurgitation is rare and causes a similar murmur but without the wide pulse pressure and collapsing pulse of aortic disease.
• C. Aortic stenosis causes an ejection systolic murmur with a slow-rising pulse, not an early diastolic murmur with a collapsing pulse.
• E. Mitral stenosis causes a mid-diastolic murmur with a normal or narrow pulse pressure, not a collapsing pulse.

Transthoracic echocardiography is the first-line investigation for any suspected valvular heart disease, as it allows direct visualisation of valve structure and motion, measurement of pressure gradients and valve area, and assessment of chamber size and ventricular function. It is non-invasive, widely available and provides the information needed to grade severity (mild, moderate, severe) and guide management decisions, including timing of referral for intervention. Cardiac catheterisation and MRI are reserved for cases where echocardiographic findings are inconclusive or when concurrent coronary assessment is needed before surgery. Exercise testing may be used cautiously in asymptomatic severe aortic stenosis to unmask symptoms, but it is not the initial diagnostic test.

• A. CT coronary angiogram assesses coronary arteries, not valve structure or function.
• B. Cardiac MRI is reserved for cases with inconclusive echocardiography or when detailed myocardial tissue characterisation is needed.
• C. Cardiac catheterisation is invasive and reserved for pre-operative coronary assessment or when echocardiography is inconclusive.
• D. Exercise testing may be used later to assess symptom status in severe disease but is not the first investigation for a new murmur.

Development of symptoms (breathlessness, syncope or angina) in severe aortic stenosis is an indication for aortic valve replacement regardless of ejection fraction, as symptomatic severe aortic stenosis carries a poor prognosis without intervention. The choice between surgical aortic valve replacement and transcatheter aortic valve implantation (TAVI) depends on surgical risk, age and frailty, decided by the multidisciplinary heart team. Watchful waiting with surveillance echocardiography is appropriate only in asymptomatic patients. Medical therapy with diuretics, beta-blockers or ACE inhibitors does not alter the natural history of the fixed mechanical obstruction and should not delay definitive valve intervention.

• B. Diuretics may provide symptomatic relief but do not address the indication for definitive valve replacement.
• C. Surveillance alone is inappropriate once symptoms develop in severe aortic stenosis; intervention is indicated.
• D. Beta-blockers do not treat the underlying mechanical obstruction and may worsen symptoms by limiting compensatory tachycardia.
• E. ACE inhibitors do not alter the natural history of severe aortic stenosis and should not substitute for valve replacement.

Infective endocarditis is diagnosed using the modified Duke criteria, which require microbiological evidence as a major criterion. Current guidance recommends taking three separate blood culture sets from different sites over a period before starting antibiotics, as this maximises the yield of the causative organism and avoids the false-negative cultures that follow premature antibiotic treatment. Echocardiography (another major criterion) is important but should follow, not precede, blood sampling in a stable patient. Inflammatory markers are supportive but non-specific and do not fulfil Duke criteria.

• A. Echocardiography is essential but blood cultures should be obtained first in a haemodynamically stable patient
• B. CRP and ESR are non-specific inflammatory markers and are not part of the microbiological major criteria
• C. Giving antibiotics before adequate cultures reduces the chance of identifying the organism and should be avoided unless the patient is septic or unstable
• E. Procalcitonin is not validated for diagnosing endocarditis and does not fulfil Duke criteria

Empirical treatment for native valve endocarditis in a patient with risk factors for resistant organisms (such as intravenous drug use) should cover Staphylococcus aureus, including meticillin-resistant strains, and streptococci. Vancomycin plus low-dose gentamicin provides broad cover against Gram-positive organisms including MRSA and enterococci while awaiting culture results, following UK microbiology guidance. Amoxicillin-based regimens are reserved for confirmed fully-sensitive streptococcal or enterococcal infection. Benzylpenicillin alone lacks staphylococcal cover, and the fluoroquinolone/macrolide options do not adequately cover the likely organisms.

• A. Amoxicillin does not reliably cover Staphylococcus aureus, including MRSA, which is a key concern in intravenous drug users
• B. Benzylpenicillin alone has inadequate staphylococcal cover and is unsuitable as sole empirical therapy
• C. This combination lacks adequate cover against Gram-positive cocci, the most likely causative organisms
• D. Clarithromycin alone is not an appropriate empirical choice for suspected bacterial endocarditis

Osler's nodes are tender, erythematous or purplish nodules found on the pulps of the fingers and toes, thought to result from immune complex deposition, and are a classic though uncommon peripheral stigma of infective endocarditis. Janeway lesions are painless erythematous or haemorrhagic macules typically on the palms or soles, caused by septic microemboli, which this patient also has but which are not the tender nodules described. Splinter haemorrhages are linear haemorrhages under the nail bed, Roth spots are retinal haemorrhages with a pale centre, and clubbing is a chronic finding unrelated to the acute lesions described.

• A. Janeway lesions are painless macules on the palms or soles, not tender nodules on the finger pulps
• B. Splinter haemorrhages are linear streaks under the nails, not nodules on the finger pulps
• D. Roth spots are retinal findings, not cutaneous lesions on the fingers
• E. Clubbing is a chronic nail-bed change, not an acute tender nodule

Acute pericarditis classically produces widespread, concave ("saddle-shaped") ST elevation across multiple leads, often accompanied by PR segment depression, reflecting diffuse epicardial inflammation rather than a single coronary territory. The pain typically worsens on lying flat and eases on sitting forward, and a pericardial friction rub supports the diagnosis. Isolated inferior ST elevation would suggest an inferior myocardial infarction rather than a diffuse inflammatory process. The other ECG patterns described relate to right ventricular hypertrophy, Wolff-Parkinson-White syndrome and myocardial ischaemia respectively, none of which fit this clinical picture.

• A. ST elevation confined to one coronary territory suggests myocardial infarction, not the diffuse process seen in pericarditis
• B. A delta wave and short PR interval are features of Wolff-Parkinson-White syndrome
• D. This pattern suggests right ventricular hypertrophy, unrelated to this presentation
• E. Diffuse ST depression suggests ischaemia or subendocardial injury, not pericarditis

Pulsus paradoxus is an exaggerated fall in systolic blood pressure of more than 10 mmHg during inspiration and is a key feature of cardiac tamponade, occurring because increased right ventricular filling during inspiration causes the interventricular septum to bulge into the fluid-restricted left ventricle, reducing left ventricular output. Combined with hypotension, elevated jugular venous pressure and quiet heart sounds, this fits Beck's triad, strongly suggesting tamponade. The other named pulse abnormalities are associated with different conditions: bisferiens with mixed aortic valve disease, alternans with severe left ventricular dysfunction, and parvus et tardus with aortic stenosis.

• A. Pulsus parvus et tardus describes a slow-rising, weak pulse typical of aortic stenosis
• B. Pulsus bisferiens, a double-peaked pulse, occurs in mixed aortic stenosis and regurgitation
• C. Pulsus alternans describes alternating pulse strength seen in severe left ventricular failure
• D. Water-hammer pulse describes a collapsing pulse seen in aortic regurgitation

Echocardiographic evidence of diastolic right ventricular collapse with haemodynamic compromise confirms cardiac tamponade, a medical emergency requiring urgent drainage of pericardial fluid, usually by ultrasound-guided pericardiocentesis, to relieve the pressure on the heart and restore cardiac output. Diuretics would worsen venous return and are contraindicated as they can precipitate cardiovascular collapse in tamponade. Anti-inflammatory treatment is appropriate for uncomplicated pericarditis but does not address the mechanical compression present here. Coronary angiography is not indicated as there is no evidence of coronary occlusion.

• B. Diuretics reduce preload and can worsen haemodynamic compromise in tamponade
• C. There is no indication of coronary artery occlusion; the problem is mechanical compression from fluid
• D. This patient is haemodynamically unstable and needs emergency drainage, not observation
• E. This treats pericarditis inflammation but does not relieve the mechanical compression causing tamponade

Viral myocarditis typically presents following a preceding viral prodrome with chest pain, palpitations and a raised troponin due to direct myocardial injury, often with normal coronary arteries on angiography, which excludes an atherosclerotic cause. Common viral causes include coxsackievirus, parvovirus B19 and adenovirus. Myocarditis carries a risk of arrhythmia and, in severe cases, of acute heart failure or sudden cardiac death, so cardiac monitoring is important. A myocardial infarction is excluded by the normal angiogram, Takotsubo typically follows acute emotional stress and shows characteristic wall motion abnormality, pulmonary embolism would not explain the troponin pattern with a normal angiogram alone, and costochondritis would not raise troponin.

• A. Pulmonary embolism does not typically follow a viral prodrome and would show different ECG and imaging findings
• B. Costochondritis does not cause troponin elevation
• C. A normal coronary angiogram excludes an acute atherosclerotic myocardial infarction
• E. Takotsubo cardiomyopathy typically follows severe emotional or physical stress and shows apical ballooning on imaging, not described here

NICE guidance recommends that a clinic blood pressure of 140/90 mmHg or higher should be confirmed with ambulatory blood pressure monitoring (ABPM) or, if ABPM is not tolerated or available, home blood pressure monitoring (HBPM) before a diagnosis of hypertension is made. This avoids overdiagnosis due to white-coat effect and ensures treatment decisions are based on an accurate average blood pressure. ABPM involves at least two measurements per hour during waking hours, with the average of at least 14 readings used. There is no indication here for urgent same-day referral, as there is no evidence of malignant hypertension or end-organ damage.

• A. Repeating clinic measurements alone does not account for white-coat effect; ambulatory or home monitoring is preferred.
• B. Secondary causes are investigated after hypertension is confirmed, not before, unless specific red flags are present.
• C. Antihypertensive drug treatment should not be started before the diagnosis is confirmed with out-of-clinic monitoring.
• D. Same-day assessment is reserved for suspected malignant hypertension, not an asymptomatic patient with a mildly raised reading.

NICE recommends a calcium channel blocker such as amlodipine as first-line treatment for patients aged 55 years or older, or for patients of Black African or African-Caribbean family origin of any age, because ACE inhibitors are generally less effective at lowering blood pressure in these groups due to lower circulating renin levels. ACE inhibitors or angiotensin receptor blockers are preferred first-line in patients under 55 without African or Caribbean family origin, or in those with type 2 diabetes regardless of age. Thiazide-like diuretics and alpha-blockers are used later in the treatment pathway if blood pressure remains uncontrolled.

• A. ACE inhibitors are less effective as first-line therapy in patients of Black African or Caribbean family origin due to lower renin activity.
• C. Alpha-blockers are reserved for resistant hypertension not controlled on combination therapy.
• D. Angiotensin receptor blockers are an alternative to ACE inhibitors but are not preferred first-line in this ethnic group for the same reason as ACE inhibitors.
• E. Thiazide-like diuretics are used as a later step if blood pressure is not controlled with calcium channel blockers and ACE inhibitors or ARBs.

ACE inhibitors block the breakdown of bradykinin, and the resulting accumulation of bradykinin in the airways is thought to cause the characteristic dry cough seen in up to 10-15% of patients. This cough is a class effect, not dose-dependent, and typically resolves within days to weeks of stopping the drug. If troublesome, the ACE inhibitor should be switched to an angiotensin receptor blocker, which does not affect bradykinin metabolism. ACE inhibitors can also rarely cause angio-oedema through the same bradykinin pathway, which is a medical emergency if it involves the airway.

• B. Interstitial lung disease would present with progressive dyspnoea and abnormal chest signs, not an isolated cough shortly after starting treatment.
• C. Gastro-oesophageal reflux is not a recognised mechanism of ACE inhibitor-induced cough.
• D. Bronchospasm from hypersensitivity would typically present with wheeze and dyspnoea, not an isolated dry cough.
• E. The cough is due to a specific biochemical mechanism (bradykinin), not a non-specific irritant effect.

This patient has malignant (accelerated) hypertension, defined as severely raised blood pressure with signs of acute end-organ damage, in this case papilloedema and retinal haemorrhages. NICE guidance recommends same-day specialist assessment for malignant hypertension to allow urgent investigation and carefully controlled blood pressure reduction, as rapid uncontrolled lowering can cause cerebral or myocardial ischaemia. Admission allows monitoring and intravenous treatment if needed, alongside assessment for other end-organ damage such as acute kidney injury or heart failure. Ambulatory monitoring and routine review are inappropriate given the evidence of target-organ damage requiring urgent intervention.

• A. Starting oral treatment in primary care without admission risks uncontrolled or overly rapid blood pressure reduction and delays detection of other complications.
• B. Weekly review is far too delayed for a patient with signs of acute end-organ damage.
• C. Ambulatory monitoring is used to confirm a diagnosis of hypertension in low-risk patients, not in a hypertensive emergency.
• D. Papilloedema with this degree of hypertension requires urgent same-day hospital assessment, not reassurance or routine referral.

Episodic headache, palpitations, sweating, and significantly raised blood pressure in a young patient are classic features of a phaeochromocytoma, a catecholamine-secreting tumour of the adrenal medulla. Diagnosis is confirmed with plasma free metanephrines or 24-hour urinary catecholamines, followed by CT or MRI adrenal imaging once biochemically confirmed. Renal artery stenosis typically presents with resistant hypertension and can cause an acute rise in creatinine after starting an ACE inhibitor, but does not cause paroxysmal catecholamine-type symptoms. Primary hyperaldosteronism classically causes hypertension with hypokalaemia, which is absent here.

• A. Cushing's syndrome causes hypertension with features such as central obesity, striae, and proximal myopathy, not paroxysmal sweating and palpitations.
• B. Renal artery stenosis causes resistant hypertension, often with a renal bruit, but not episodic sweating and palpitations.
• D. Coarctation of the aorta typically presents with radiofemoral delay and a blood pressure difference between arms, not episodic autonomic symptoms.
• E. Primary hyperaldosteronism typically causes hypokalaemia, which is not present in this patient.

This patient has acute limb ischaemia, most likely due to embolism from atrial fibrillation, presenting with the classic features of pain, pallor, perishingly cold limb, pulselessness, paraesthesia, and paralysis (the six Ps), with sensory and motor loss indicating a threatened limb. This is a vascular emergency requiring immediate anticoagulation with intravenous or subcutaneous heparin to prevent clot propagation and urgent discussion with the on-call vascular surgical team for consideration of embolectomy, thrombolysis, or bypass. Delaying for imaging such as duplex ultrasound or ABPI in a patient with a threatened limb risks irreversible tissue loss. Any delay beyond the window for revascularisation markedly increases the risk of limb loss.

• A. Outpatient review is inappropriate for an acutely ischaemic limb; this requires immediate inpatient management.
• B. Elevating the leg would worsen ischaemia by reducing arterial perfusion, and delayed reassessment risks irreversible damage.
• C. ABPI is unreliable and unnecessary in acute severe ischaemia and should not delay urgent treatment.
• D. Imaging should not delay anticoagulation and urgent surgical referral when there is sensory and motor loss indicating a threatened limb.

This patient has a ruptured abdominal aortic aneurysm (AAA) with haemodynamic instability, indicated by hypotension, tachycardia and a pulsatile abdominal mass. A haemodynamically unstable patient with a strongly suspected ruptured AAA should be taken straight to theatre for emergency surgical repair without waiting for imaging, as delay increases mortality. Permissive hypotension (keeping systolic blood pressure around 90-100 mmHg) is used during transfer rather than aggressive fluid resuscitation, as over-resuscitation can worsen bleeding by dislodging clot. Vascular surgeons should be alerted immediately and the patient should not leave the resuscitation area for scans that would delay definitive treatment.

• B. This would delay treatment and is not indicated; the clinical picture does not suggest pancreatitis or a thoracic cause.
• C. Aggressive fluid resuscitation to a normal blood pressure can worsen haemorrhage by disrupting the tamponading clot; permissive hypotension is preferred.
• D. Ultrasound can confirm an AAA but adds delay and is unnecessary when the diagnosis is already clinically clear in an unstable patient.
• E. CT angiography would delay life-saving surgery in an unstable patient; it is reserved for stable patients with uncertain diagnosis.

Sudden, severe, tearing chest pain radiating to the back, combined with a significant blood pressure discrepancy between the two arms (more than 20 mmHg), is highly suggestive of acute aortic dissection. The pain results from the intimal tear and propagation of blood within the aortic wall, and the arm pressure difference reflects differential involvement of the subclavian or brachiocephalic arteries. Hypertension is the leading risk factor. The next step would be an urgent CT aortogram if the patient is haemodynamically stable, or transoesophageal echocardiography if not.

• B. STEMI typically causes crushing central chest pain without a tearing quality or interarm blood pressure difference, and would show ST elevation on ECG.
• C. Musculoskeletal pain would not explain the interarm blood pressure difference or the severity and sudden onset described.
• D. PE typically presents with pleuritic chest pain, dyspnoea and tachycardia, but does not cause tearing back pain or interarm blood pressure differences.
• E. Pericarditis causes sharp pain that is positional and worsened by inspiration, with no interarm blood pressure difference.

This is a Stanford type B aortic dissection, as it involves only the descending aorta distal to the left subclavian artery without involvement of the ascending aorta. Uncomplicated type B dissections are managed medically with strict blood pressure and heart rate control, typically using intravenous beta-blockers, to reduce aortic wall stress and limit propagation. Surgical or endovascular intervention is reserved for complicated type B dissections, such as those with malperfusion, rupture, or refractory pain. In contrast, Stanford type A dissections, involving the ascending aorta, require emergency surgical repair due to the high risk of complications such as aortic rupture or cardiac tamponade.

• A. Aortic root replacement is required for type A dissections affecting the aortic root, not an isolated descending aortic dissection.
• B. PCI is used for coronary artery occlusion, not for management of aortic dissection.
• C. Emergency open surgery is the management for type A dissections involving the ascending aorta, not uncomplicated type B.
• D. Thrombolysis would worsen bleeding in a dissection and is contraindicated.

NICE guidance recommends a direct oral anticoagulant (DOAC) such as apixaban or rivaroxaban as first-line treatment for confirmed DVT in most patients, as these do not require routine monitoring and have a lower bleeding risk than warfarin in many patients. Apixaban can be started immediately without the need for initial parenteral anticoagulation, unlike dabigatran or edoxaban, which require five to ten days of heparin lead-in. Warfarin is reserved for patients in whom DOACs are unsuitable, such as those with severe renal impairment or antiphospholipid syndrome, and requires bridging with heparin due to its delayed onset of anticoagulant effect.

• A. Fondaparinux is not first-line treatment for confirmed DVT in patients without contraindications to DOACs.
• C. This LMWH-warfarin combination was standard practice historically but has been superseded by DOACs as first-line treatment.
• D. Unfractionated heparin infusion is reserved for specific situations such as severe renal impairment or where rapid reversal may be needed, not first-line for routine DVT.
• E. Warfarin alone would not provide adequate initial anticoagulation due to its delayed onset and initial procoagulant effect; it requires heparin bridging.

NICE recommends offering atorvastatin 20 mg daily for primary prevention of cardiovascular disease in adults with a QRISK3 score of 10% or more over 10 years. This patient's QRISK3 score of 12% exceeds this threshold, making statin therapy appropriate alongside lifestyle advice on diet, exercise, alcohol and smoking. Atorvastatin 80 mg is used for secondary prevention in patients with established cardiovascular disease, not for primary prevention. Lipid levels and blood pressure in this patient do not independently mandate separate drug treatment outside of the statin recommendation.

• A. Ezetimibe monotherapy is not first-line; statins are the first-line lipid-lowering therapy for primary prevention.
• B. This high dose is used for secondary prevention in patients with established cardiovascular disease, not for primary prevention.
• C. A QRISK3 score of 12% exceeds the 10% threshold for intervention, so statin therapy should be offered now rather than deferred.
• D. His blood pressure of 134/82 mmHg does not meet the threshold for pharmacological treatment of hypertension.

This patient has statin-induced myopathy with a significantly raised creatine kinase, consistent with statin-related muscle toxicity, which can progress to rhabdomyolysis if the statin is continued. The statin should be stopped and renal function checked, as rhabdomyolysis can cause acute kidney injury from myoglobin-induced tubular damage. Once symptoms resolve and creatine kinase normalises, a lower dose or an alternative statin can be cautiously reintroduced, but continuing or switching to another statin at this stage is inappropriate given the markedly elevated creatine kinase and ongoing symptoms.

• A. Reducing the dose while continuing the statin does not address the acute risk posed by significantly elevated creatine kinase.
• C. Switching statins while symptomatic and with a significantly raised creatine kinase is inappropriate before the current episode has resolved.
• D. Colchicine is not indicated for statin-induced myopathy and would not address the underlying muscle toxicity.
• E. Continuing the statin risks progression to rhabdomyolysis and acute kidney injury given the markedly elevated creatine kinase.

Smoking cessation is one of the most effective secondary prevention measures after myocardial infarction, and continuing to smoke substantially increases the risk of reinfarction and death. NICE recommends that all smokers, particularly after a cardiovascular event, be offered referral to specialist smoking cessation services, which combine behavioural support with pharmacotherapy such as varenicline, bupropion or nicotine replacement therapy to maximise quit rates. Nicotine replacement therapy is not contraindicated post-myocardial infarction and is considered safer than continued smoking. Complete abstinence, rather than reduction, is the goal, and combining support methods gives the best chance of sustained cessation given his history of relapse.

• A. Smoking cessation is a crucial and independent component of secondary prevention and should be actively pursued alongside medication.
• B. E-cigarettes may be offered as a harm-reduction option for smoking cessation in those who have struggled with other methods.
• C. Cutting down still carries significant cardiovascular risk; complete cessation is the recommended goal.
• E. Nicotine replacement therapy is not contraindicated after myocardial infarction and is considered safer than continued smoking.

Very high LDL-cholesterol (often >6.5 mmol/L) with tendon xanthomata, corneal arcus or xanthelasma, and a family history of premature coronary artery disease (before 55 years in men, 60 years in women) in a first-degree relative strongly suggests familial hypercholesterolaemia. NICE CG71 recommends using the Simon Broome or Dutch Lipid Clinic Network criteria, which combine these clinical, biochemical and family history features to make the diagnosis. Patients meeting these criteria should be referred to a specialist lipid clinic for confirmation, consideration of genetic testing and cascade testing of relatives. The normal body mass index and blood pressure argue against a secondary cause for the hyperlipidaemia.

• A. Nephrotic syndrome causes hyperlipidaemia but is associated with oedema and heavy proteinuria, not tendon xanthomata.
• B. Metabolic syndrome requires features such as obesity, hypertension and insulin resistance, none of which are present here.
• C. Polygenic hypercholesterolaemia produces milder lipid elevations without tendon xanthomata or such a strong family history of early cardiac death.
• D. Hypothyroidism can cause secondary hyperlipidaemia but does not produce tendon xanthomata or this degree of LDL elevation with a strong family history of premature coronary disease.